Volatility in European stock markets
European stock exchanges are going through a phase of volatility, with the Ftse Mib in Piazza Affari closing substantially unchanged at 36,191 points. This scenario is influenced by several factors, including concerns related to Chinese artificial intelligence, in particular the DeepSeek model, which has had a significant impact on the performance of technology stocks on Wall Street. The Nasdaq registered a 3% decline, while the S&P 500 saw a 2% decrease. These events have raised questions about market stability and future prospects
.
Significant movements in the stock market
Among the stocks in evidence, Hera saw an increase of 3.8% thanks to a recently presented strategic plan, while Generali gained 1.9%, influenced by the situation between MPS and Mediobanca. On the contrary, Prysmian fell by 8.75%, due to forecasts of a decrease in electricity demand for data centers, linked to the potential development of DeepSeek. In addition, Morgan Stanley has revised Prysmian’s target price, bringing it to 64 euros, confirming the recommendation to keep the stock
.
Economic Indicators and Future Forecasts
On
the macroeconomic front, the German Ifo index showed a deterioration in business expectations for January, while in the United States, sales of new homes in December exceeded expectations. Investors are now closely monitoring the 2-year and 5-year Treasury auctions, as well as upcoming Fed and ECB meetings, which could further influence the market.
The Btp-Bund spread remains around 110 basis points, with the Italian stock at 3.63% and the German one at 2.53%.
Commodity and cryptocurrency trends
In the commodities market, Brent oil continues to fall, reaching 76.4 dollars per barrel, while gold depreciates to 2,738 dollars an ounce. On the currency front, the euro/dollar rose above the 1.05 mark, while the dollar/yen fell to 154.3. Among cryptocurrencies, Bitcoin has once again exceeded 100,000 dollars, attracting the attention of investors
.
News from the biotech sector
Another important news comes from the biotech sector, with Metsera preparing to list on Nasdaq through an initial public offering of 17,187,500 shares, aiming to raise up to 292.2 million dollars. The IPO expects a price per share of between 15 and 17 dollars. Metsera specializes in the development of innovative peptides for the treatment of obesity and related conditions, aiming to improve the efficacy and production of its drugs
.
Performance by the Ermenegildo Zegna group
Finally, the Ermenegildo Zegna group reported a 2.2% increase in revenues in 2024, with a particularly strong performance in the fourth quarter, thanks to an 8.4% increase in the Zegna brand. These results highlight the brand’s resilience in the current market environment and its ability to attract consumers despite global economic challenges
.